



European
Crohn's and Colitis
Organisation

Inflammatory Bowel Diseases

IBD Intensive Course for Trainees



Programme 2016-2022

www.ecco-ibd.eu

20th IBD Intensive Course for Trainees

Date: Wednesday, February 16, 2022
Time: 08:00-17:20
Organisation: EduCom
Recommended for: Junior gastroenterologists
Registration: ECCO Membership 2022 required
Upon invitation only
CME accreditation: 6 CME Credits; prerequisite: completion of the online evaluation form

Wednesday, February 16, 2022

(as per February 9, 2022)

08:00 - 08:15	Arrival & download of ECCO IBD App
08:15 - 08:20	1: Welcome & Introduction from the course director F. Magro, Porto, Portugal L. Peyrin-Biroulet, Vandœuvre-Lès-Nancy, France H. Yanai, Petah Tikva, Israel
08:20 - 10:20	Session 1: Introduction and case-based management on conventional IBD therapies Lead discussant: J. Lindsay, London, United Kingdom
08:20 - 09:00	2: IBD: Epidemiology, immunopathogenesis, and their relevance to therapeutics I. Dotan, Petah Tikva, Israel
09:00 - 09:20	3: 5-ASA compounds K. Karmiris, Heraklion, Greece
09:20 - 09:40	4: Thiopurines J. Torres, Loures, Portugal
09:40 - 10:00	5: Methotrexate P. Juillerat, Bern, Switzerland
10:00 - 10:20	6: Steroids H. Yanai, Petah Tikva, Israel
10:20 - 10:40	Break
10:40 - 12:30	Session 2: Case-based management of conventional IBD therapies Lead discussant: B. Siegmund, Berlin, Germany
10:40 - 11:10	7: Anti-TNF agents and TDM P. Michetti, Lausanne, Switzerland
11:10 - 11:30	8: Anti-integrins J. Lindsay, London, United Kingdom
11:30 - 11:50	9: Anti-IL 12/23 M. Ferrante, Leuven, Belgium
11:50 - 12:10	10: JAK inhibitors S. Danese, Milan, Italy
12:10 - 12:30	11: Medication in the pipeline L. Peyrin-Biroulet, Vandœuvre-Lès-Nancy, France

12:30 - 14:00 Break	
14:00 - 14:30	12: Positioning therapeutic strategies in IBD S. Ben-Horin, Ramat Gan, Israel
14:30 - 15:30	Session 3: Round tables – 7 Themes / clinical cases discussion – Part 1 Lead discussant: H. Yanai, Petah Tikva, Israel
14:30 - 15:30	13a: Pregnancy I. Dotan, Petah Tikva, Israel J. van der Woude, Rotterdam, The Netherlands 13b: Extraintestinal manifestations K. Karmiris, Heraklion, Greece P. Lakatos, Budapest, Hungary; Montreal, Canada 13c: When and how to start biologics? G. Mantzaris, Athens, Greece B. Siegmund, Berlin, Germany
15:30 - 15:50 Break	
15:50 - 17:20	Session 3: Round tables – 7 Themes / clinical cases discussion – Part 2
15:50 - 17:10	13d: Complications associated with anti-TNF therapy S. Ben-Horin, Ramat Gan, Israel Y. Chowers, Haifa, Israel 13e: Therapeutic Drug Monitoring F. Baert, Roeselare, Belgium P. Juillerat, Bern, Switzerland 13f: Exit strategy M. Ferrante, Leuven, Belgium J. Torres, Loures, Portugal 13g: Therapeutic Endoscopy in IBD P. Michetti, Lausanne, Switzerland H. Yanai, Petah Tikva, Israel
17:10 - 17:20	14: Summary and conclusions H. Yanai, Petah Tikva, Israel

19th IBD Intensive Course for Trainees

Date: Friday, July 2, 2021
Time: 08:00-13:45
Organisation: EduCom
Recommended for: Junior gastroenterologists
Registration: ECCO Membership 2021 required. Upon invitation only
CME accreditation: 5 CME credits; prerequisite: completion of the online evaluation form

Friday, July 2, 2021

08:00 - 08:05	1: Welcome & Introduction from the course director H. Yanai, Petah Tikva, Israel F. Magro Dias, Porto, Portugal L. Peyrin-Biroulet, Vandœuvre-Lès-Nancy, France
08:05 - 09:30	Session 1: Introduction and case-based management on conventional IBD therapies Lead discussant: J. Lindsay, London, United Kingdom
08:05 - 08:30	2: IBD: Epidemiology, immunopathogenesis, and their relevance to therapeutics I. Dotan, Petah Tikva, Israel
08:30 - 08:45	3: 5-ASA compounds S. Hanauer, Chicago, United States
08:45 - 09:00	4: Thiopurines P. Irving, London, United Kingdom
09:00 - 09:15	5: Methotrexate P. Juillerat, Bern, Switzerland
09:15 - 09:30	6: Steroids H. Yanai, Petah Tikva, Israel
09:30 - 09:45	Break
09:45 - 11:25	Session 2: Case-based management of conventional IBD therapies Lead discussant: A. Dignass, Frankfurt, Germany
09:45 - 10:05	7: Anti-TNF agents and TDM P. Michetti, Lausanne, Switzerland
10:05 - 10:20	8: Anti-integrins J. Lindsay, London, United Kingdom
10:20 - 10:35	9: Anti-IL 23 M. Ferrante, Leuven, Belgium
10:35 - 10:50	10: JAK inhibitors S. Vermeire, Leuven, Belgium
10:50 - 11:05	11: Medication in the pipeline L. Peyrin-Biroulet, Vandœuvre-Lès-Nancy, France
11:05 - 11:25	12: Positioning therapeutic strategies in IBD S. Ben-Horin, Ramat Gan, Israel
11:25 - 11:55	Break

11:55 - 13:40	Session 3: Round tables – 7 Themes / clinical cases discussion
11:55 - 13:40	13a: Pregnancy J. van der Woude, Rotterdam, The Netherlands I. Dotan, Petah Tikva, Israel 13b: Extraintestinal manifestations K. Karmiris, Heraklion, Greece P. Lakatos, Budapest, Hungary 13c: When and how to start biologics? A. Dignass, Frankfurt, Germany G. Mantzaris, Athens, Greece 13d: Complications associated with anti-TNF therapy S. Ben-Horin, Ramat Gan, Israel Y. Chowers, Haifa, Israel 13e: Therapeutic Drug Monitoring P. Juillerat, Bern, Switzerland S. Vavricka, Zurich, Switzerland 13f: Exit strategy M. Ferrante, Leuven, Belgium G. Fiorino, Rozzano, Italy 13g: Therapeutic Endoscopy in IBD P. Michetti, Lausanne, Switzerland H. Yanai, Petah Tikva, Israel
13:40 - 13:45	14: Summary and conclusions H. Yanai, Petah Tikva, Israel

18th IBD Intensive Advanced Course

Date: Wednesday-Thursday, February 12-13, 2020
Time: Wednesday, February 12: 08:00-17:00
 Thursday, February 13: 07:30-12:00
Organisation: EduCom
Target audience: Junior gastroenterologists
Registration: ECCO Membership 2020 required. No onsite registration.
CME accreditation: 10 CME Credits; prerequisite: completion of the online evaluation form.

Wednesday, February 12, 2020

*Strauss 3, Ground Level, Reed Messe Wien
(as of January 15, 2020)*

08:00 - 08:15	Arrival & download of ECCO IBD App
08:15 - 08:30	1: Welcome & Introduction from the course director S. Danese, Milan, Italy J. Lindsay, London, United Kingdom P. Juillerat, Bern, Switzerland
08:30 - 10:30	Session 1: Introduction and case-based management on conventional IBD Therapies Lead discussant: J. Lindsay, London, United Kingdom
08:30 - 09:00	2: IBD: Epidemiology, immunopathogenesis, and their relevance to therapeutics I. Dotan, Petah Tikva, Israel
09:00 - 09:20	3: 5-ASA compounds H. Yanai, Petah Tikva, Israel
09:20 - 09:40	4: Thiopurines P. Irving, London, United Kingdom
09:40 - 10:00	5: Methotrexate P. Juillerat, Bern, Switzerland
10:00 - 10:20	6: Steroids K. Katsanos, Ioannina, Greece
10:20 - 10:30	Discussion
10:30 - 10:50	Coffee break
10:50 - 12:30	Session 2: Case-based management of conventional IBD Therapies Lead discussant: A. Dignass, Frankfurt. Germany
10:50 - 11:10	7: Anti-TNF agents P. Michetti, Lausanne, Switzerland
11:10 - 11:30	8: Anti-integrins J. Lindsay, London, United Kingdom
11:30 - 11:50	9: Ustekinumab S. Vermeire, Leuven, Belgium

11:50 - 12:10	10: Tofacitinib F. Rieder, Cleveland, United States
12:10 - 12:30	11: Small molecules and biologics in the pipeline L. Peyrin-Biroulet, Vandœuvre-les-Nancy, France
12:30 - 14:00	Lunch break
14:00 - 15:30	Session 3: Round tables – 7 Themes / clinical cases discussion – Part 1
14:00 - 15:30	12a: Pregnancy J. van der Woude, Rotterdam, The Netherlands I. Dotan, Petah Tikva, Israel 12b: Extraintestinal manifestations K. Katsanos, Ioannina, Greece P. Lakatos, Budapest, Hungary; Montreal, Canada 12c: When and how to stop biologics? A. Dignass, Frankfurt, Germany G. Mantzaris, Athens, Greece 12d: Complications associated with anti-TNF therapy S. Ben-Horin, Ramat Gan, Israel Y. Chowers, Haifa, Israel 12e: Therapeutic Drug Monitoring P. Juillerat, Bern, Switzerland F. Baert, Roeselare, Belgium 12f: Exit strategy M. Ferrante, Leuven, Belgium J. Torres, Loures, Portugal 12g: Endoscopy in IBD P. Michetti, Lausanne, Switzerland H. Yanai, Petah Tikva, Israel
15:30 - 15:50	Coffee break
15:50 - 17:00	Session 3: Round tables – 7 Themes / clinical cases discussion – Part 2
15:50 - 17:00	12a: Pregnancy J. van der Woude, Rotterdam, The Netherlands I. Dotan, Petah Tikva, Israel 12b: Extraintestinal manifestations K. Katsanos, Ioannina, Greece P. Lakatos, Budapest, Hungary; Montreal, Canada 12c: When and how to stop biologics? A. Dignass, Frankfurt, Germany G. Mantzaris, Athens, Greece 12d: Complications associated with anti-TNF therapy S. Ben-Horin, Ramat Gan, Israel Y. Chowers, Haifa, Israel 12e: Therapeutic Drug Monitoring P. Juillerat, Bern, Switzerland F. Baert, Roeselare, Belgium 12f: Exit strategy M. Ferrante, Leuven, Belgium J. Torres, Loures, Portugal 12g: Therapeutic Endoscopy in IBD P. Michetti, Lausanne, Switzerland H. Yanai, Petah Tikva, Israel

Thursday, February 13, 2020

Strauss 3, Ground Level, Reed Messe Wien

(as of January 15, 2020)

07:30 - 09:30	Session 4: Interactive case discussions Lead discussants: P. Juillerat, Bern, Switzerland A. López-Sanromán, Madrid, Spain
07:30 - 08:00	13: Investigation and management of early Mild/Moderate Crohn's Disease Case presentation: T. Raine, Cambridge, United Kingdom Discussion: L. Egan, Galway, Ireland
08:00 - 08:05	Discussion
08:05 - 08:40	14: Management of perianal CD A. López-Sanromán, Madrid, Spain P. Kotze, Curitiba, Brazil
08:40 - 08:45	Discussion
08:45 - 09:30	15: Optimal management of patient with Severe Crohn's Disease treated with anti-TNF agents Case presentation: D. Bettenworth, Münster, Germany Discussion: P. Juillerat, Bern, Switzerland P. Kotze, Curitiba, Brazil
09:30 - 09:45	Coffee break
09:45 - 11:45	Session 5: Special case scenarios Lead discussant: G. Mantzaris, Athens, Greece
09:45 - 10:15	16: Management of refractory pouchitis I. Dotan, Petah Tikva, Israel
10:15 - 10:45	17: Management of Acute Severe Ulcerative Colitis D. Laharie, Pessac, France
10:45 - 11:15	18: Pre- and postoperative management of Crohn's Disease G. Doherty, Dublin, Ireland
11:15 - 11:45	Discussion
11:45 - 12:00	19: Feedback & Closing remarks P. Juillerat, Bern, Switzerland

17th IBD Intensive Advanced Course

Date:	Wednesday-Thursday, March 6-7, 2019
Time:	Wednesday, March 6: 08:00-16:45 Thursday, March 7: 07:30-12:00
Organisation:	EduCom
Target audience:	Junior gastroenterologists
Registration:	Upon invitation only. No onsite registration.
CME accreditation:	10 CME Credits; prerequisite: completion of the online evaluation form.

Wednesday, March 6, 2019

Programme overview (as of February 1, 2019)

HB4 M1-2, Hall B, Bella Center

08:00 - 08:15	Arrival & distribution of voting pads
08:15 - 08:30	1: Welcome Silvio Danese, Milan, Italy James Lindsay, London, United Kingdom
08:30 - 09:15	Session 1: Pathogenesis Lead discussant: Yehuda Chowers, Haifa, Israel
08:30 - 08:45	2: Exosome Jonas Halfvarson, Örebro, Sweden
08:45 - 09:00	3: Genetics Siew Ng, Hong Kong, China
09:00 - 09:15	4: Inflammatory pathways Yehuda Chowers, Haifa, Israel
09:15 - 09:35	Coffee break
09:35 - 11:20	Session 2: Part I: Case-based management of IBD therapies Lead discussant: Peter Irving, London, United Kingdom
09:35 - 10:05	5: 5-ASA compounds Gerhard Rogler, Zurich, Switzerland
10:05 - 10:20	6: Thiopurines Peter Irving, London, United Kingdom
10:20 - 10:35	7: Methotrexate Pascal Juillerat, Bern, Switzerland
10:35 - 10:50	8: Steroids Fernando Gomollón Garcia, Zaragoza, Spain
10:50 - 11:05	9: Anti-TNF agents Filip Baert, Roeselare, Belgium
11:05 - 11:20	10: Anti-integrines James Lindsay, London, United Kingdom

Wednesday, March 6, 2019, cont.

Programme overview (as of February 1, 2019)

HB4 M1-2, Hall B, Bella Center

11:20 - 12:05		Session 2: Part II: New biologics and small molecules Lead discussant: Axel Dignass, Frankfurt, Germany
	11:20 - 11:35	11: Ustekinumab Marc Ferrante, Leuven, Belgium
	11:35 - 11:50	12: Tofacitinib Florian Rieder, Cleveland, United States
	11:50 - 12:05	13: Other small molecules (apremilast/ozanimod) Laurent Peyrin Biroulet, Vandœuvre-lès-Nancy, France
12:05 - 13:25		Lunch break
13:25 - 14:55		Session 3: Seminars: Part I: Special clinical situations
	13:25 - 14:10	EITHER: 14a. Managing IBD and pregnancy (HB4 M1-2, Hall B, Bella Center) Iris Dotan, Petah Tikva, Israel Janneke van der Woude, Rotterdam, The Netherlands OR: 14b. Managing extraintestinal manifestations of IBD (B4 M10, Hall B, Bella Center) Peter Lakatos, Budapest, Hungary; Montreal, Canada Stephan Vavricka, Zurich, Switzerland
	14:10 - 14:55	EITHER: 14a. Managing IBD and pregnancy (B4 M10, Hall B, Bella Center) Iris Dotan, Petah Tikva, Israel Janneke van der Woude, Rotterdam, The Netherlands OR: 14b. Managing extraintestinal manifestations of IBD (HB4 M1-2, Hall B, Bella Center) Peter Lakatos, Budapest, Hungary; Montreal, Canada Stephan Vavricka, Zurich, Switzerland
14:55 - 15:15		Coffee break
15:15 - 16:45		Session 3: Seminars: Part II: Long term management
	15:15 - 16:00	EITHER: 15a. Managing complications associated with anti-TNF therapy (HB4 M1-2, Hall B, Bella Center) Shomron Ben-Horin, Ramat Gan, Israel Joana Torres, Lisbon, Portugal OR: 15b. Endoscopy in IBD incl. chromo-endoscopy, balloon dilatation (B4 M10, Hall B, Bella Center) Pierre Michetti, Lausanne, Switzerland Henit Yanai, Petah Tikva, Israel
	16:00 - 16:45	EITHER: 15a. Managing complications associated with anti-TNF therapy (B4 M10, Hall B, Bella Center) Shomron Ben-Horin, Ramat Gan, Israel Joana Torres, Lisbon, Portugal OR: 15b. Endoscopy in IBD incl. chromo-endoscopy, balloon dilatation (HB4 M1-2, Hall B, Bella Center) Pierre Michetti, Lausanne, Switzerland Henit Yanai, Petah Tikva, Israel

Thursday, March 7, 2019

Programme overview (as of February 1, 2019)

HB4 M1-2, Hall B, Bella Center

07:30 - 09:30		Session 4: Interactive case discussions Lead discussants: Pascal Juillerat, Bern, Switzerland Antonio López-Sanromán, Madrid, Spain
	07:30 - 08:00	16: Investigation and management of early Mild/Moderate Crohn's Disease Case presentation: Tim Raine, Cambridge, United Kingdom Discussion: Larry Egan, Galway, Ireland
	08:00 - 08:05	Discussion
	08:05 - 08:40	17: Management of perianal CD Paulo Kotze, Curitiba, Brazil Antonio López-Sanromán, Madrid, Spain
	08:40 - 08:45	Discussion/Questions
	08:45 - 09:30	18: Optimal management of patient with Severe Crohn's Disease treated with anti-TNF agents Case presentation: Dominik Bettenworth, Münster, Germany Discussion: Pascal Juillerat, Bern, Switzerland Paulo Kotze, Curitiba, Brazil
09:30 - 09:45		Coffee break
09:45 - 11:45		Session 5: Special case scenarios Lead discussant: Gerassimos Mantzaris, Athens, Greece
	09:45 - 10:15	19: Medical management of Acute Severe Ulcerative Colitis David Laharie, Bordeaux, France
	10:15 - 10:45	20: Pre- and postoperative management of Crohn's Disease Glen Doherty, Dublin, Ireland
	10:45 - 11:15	21: Management of refractory pouchitis Iris Dotan, Petah Tikva, Israel
	11:15 - 11:45	Discussion / Q&A Session
11:45 - 12:00		22: Feedback and closing remarks Pascal Juillerat, Bern, Switzerland

16th IBD Intensive Advanced Course

Date:	February 14-15, 2018
Time:	February 14: 08:45-16:45 February 15: 07:45-12:00
Organisation:	EduCom
Target audience:	Junior gastroenterologists
Registration:	Upon invitation
CME accreditation:	9 CME credits, upon return of an evaluation form filled in online

Wednesday, February 14, 2018

Programme overview (as of January 15, 2018)

Strauss 3, Congress Centre, Messe Wien

08:45 - 09:00	Arrival & distribution of voting pads	
09:00 - 09:10	1: Welcome	- Julían Panés, Barcelona, Spain - James Lindsay, London, United Kingdom
09:10 - 10:05	Session 1: Pathogenesis Lead discussant: James Lindsay, London, United Kingdom	
	09:10 - 09:25	2: Exposome Jonas Halfvarson, Örebro, Sweden
	09:25 - 09:40	3: Genetics Miles Parkes, Cambridge, United Kingdom
	09:40 - 09:55	4: Inflammatory pathways Yehuda Chowers, Haifa, Israel
	09:55 - 10:05	Discussion / Questions
10:05 - 10:20	Coffee break	
10:20 - 11:35	Session 2: Drug management sessions. Part I: Conventional drugs Lead discussant: Antonio López-Sanromán, Madrid, Spain	
	10:20 - 10:40	5: 5-ASA compounds Gerhard Rogler, Zurich, Switzerland
	10:40 - 11:00	6: Thiopurines Peter Irving, London, United Kingdom
	11:00 - 11:15	7: Methotrexate Pascal Juillerat, Bern, Switzerland
	11:15 - 11:35	8: Steroids Stephan Vavricka, Zurich, Switzerland

Wednesday, February 14, 2018, cont.

Programme overview (as of January 15, 2018)

Strauss 3, Congress Centre, Messe Wien

11:35 - 12:55	Session 2: Drug management sessions. Part II: Biologics Lead discussant: Séverine Vermeire, Leuven, Belgium
11:35 - 11:55	9: Anti-TNF agents Filip Baert, Roeselare, Belgium
11:55 - 12:10	10: Vedolizumab James Lindsay, London, United Kingdom
12:10 - 12:25	11: Ustekinumab Marc Ferrante, Leuven, Belgium
12:25 - 12:40	12: Tofacitinib Séverine Vermeire, Leuven, Belgium
12:40 - 12:55	Discussion / Questions
12:55 - 13:30	Lunch break
13:30 - 15:00	Session 3: Seminars: Part I: Special clinical situations
13:30 - 14:15	EITHER: 13a. Managing IBD and pregnancy (Strauss 3, Congress Centre, Messe Wien) Iris Dotan, Petah Tikva, Israel Janneke van der Woude, Rotterdam, The Netherlands OR 13b. Managing extraintestinal manifestations of IBD (Schubert 6, Congress Centre, Messe Wien) Peter Lakatos, Budapest, Hungary; Montreal, Canada Stephan Vavricka, Zurich, Switzerland
14:15 - 15:00	EITHER: 14a. Managing IBD and pregnancy (Schubert 6, Congress Centre, Messe Wien) Iris Dotan, Petah Tikva, Israel Janneke van der Woude, Rotterdam, The Netherlands OR 14b. Managing extraintestinal manifestations of IBD (Strauss 3, Congress Centre, Messe Wien) Peter Lakatos, Budapest, Hungary; Montreal, Canada Stephan Vavricka, Zurich, Switzerland
15:00 - 15:15	Coffee break
15:15 - 16:45	Session 3: Seminars: Part II : Long term management
15:15 - 16:00	EITHER: 15a. Managing complications associated with anti-TNF therapy (Strauss 3, Congress Centre, Messe Wien) Shomron Ben-Horin, Ramat Gan, Israel Axel Dignass, Frankfurt, Germany OR 15b. Endoscopy in IBD incl. chromo-endoscopy, balloon dilatation (Schubert 6, Congress Centre, Messe Wien) Marc Ferrante, Leuven, Belgium Pierre Michetti, Lausanne, Switzerland
16:00 - 16:45	EITHER: 16a. Managing complications associated with anti-TNF therapy (Schubert 6, Congress Centre, Messe Wien) Shomron Ben-Horin, Ramat Gan, Israel Axel Dignass, Frankfurt, Germany OR 16b. Endoscopy in IBD incl. chromo-endoscopy, balloon dilatation (Strauss 3, Congress Centre, Messe Wien) Marc Ferrante, Leuven, Belgium Pierre Michetti, Lausanne, Switzerland

Thursday, February 15, 2018

Programme overview (as of January 15, 2018)

Strauss 3, Congress Centre, Messe Wien

07:45 - 09:25		Session 4: Interactive case discussions Lead discussant: Ailsa Hart, London, United Kingdom
	07:45 - 08:30	17: Case-based discussion: Fistulising Crohn's Disease: Medical and surgical approaches Paulo Kotze, Curitiba, Brazil; Calgary, Canada Antonio López-Sanromán, Madrid, Spain
	08:30 - 08:35	Discussion
	08:35 - 09:20	18: Case-based discussion: Optimal management of patient with severe Crohn's Disease treated with anti-TNF agents Case presentation: Michael Fitzpatrick, Oxford, United Kingdom Discussion: Simon Travis, Oxford, United Kingdom
	09:20 - 09:25	Discussion/Questions
09:25 - 09:45		Coffee break
09:45 - 11:50		Session 5: Special cases scenarios Lead discussant: Gerassimos Mantzaris, Athens, Greece
	09:45 - 10:15	19: Medical management of Acute Severe Ulcerative Colitis Corey Siegel, Lebanon, United States
	10:15 - 10:45	20: Management of refractory pouchitis Iris Dotan, Petah Tikva, Israel
	10:45 - 11:15	21: Pre- and postoperative management of Crohn's Disease Glen Doherty, Dublin, Ireland
	11:15 - 11:50	22: Case based discussion: Investigation and management of mild/moderate Crohn's Disease Case presentation: Tim Raine, Cambridge, United Kingdom Discussion: Laurence Egan, Galway, Ireland
11:50 - 12:00		Feedback and closing remarks Pascal Juillerat, Bern, Switzerland

15th IBD Intensive Advanced Course

Date:	February 15-16, 2017
Time:	IBD Advanced Course: Feb 15, 2017: 08:00-15:45 February 16, 2017: 08:00-12:30 Industry sponsored satellite symposium: Feb 15, 2017: 16:00-17:00
Organisation:	EduCom
Target audience:	Junior gastroenterologists
Registration:	Upon invitation
CME accreditation:	9 CME credits, upon return of an evaluation form filled in online

Wednesday, February 15, 2017

Programme overview (as of January 16, 2017)

Room 111, Level 1, CCIB

07:45 - 08:00	Arrival & distribution of voting pads
08:00 - 08:10	1: Welcome Julián Panés, Barcelona, Spain Gerassimos Mantzaris, Athens, Greece
08:10 - 08:30	2: Pre-course test Peter Irving, London, United Kingdom
08:30 - 09:30	Session 1: Pathogenesis Lead discussant: James Lindsay, London, United Kingdom
08:30 - 08:50	3: Exposome Jonas Halfvarson, Örebro, Sweden
08:50 - 09:10	4: Genetics Miles Parkes, Cambridge, United Kingdom
09:10 - 09:30	5: Inflammatory pathways Yehuda Chowers, Haifa, Israel
09:30 - 09:50	Coffee break
09:50 - 11:10	Session 2: Drug management sessions. Part I: Conventional drugs Lead discussant: Pascal Juillerat, Bern, Switzerland
09:50 - 10:10	6: 5-ASA compounds Gerhard Rogler, Zurich, Switzerland
10:10 - 10:30	7: Thiopurines Peter Irving, London, United Kingdom
10:30 - 10:50	8: Methotrexate Pascal Juillerat, Bern, Switzerland
10:50 - 11:10	9: Steroids Stephan Vavricka, Zurich, Switzerland

Wednesday, February 15, 2017, cont.

Programme overview (as of January 16, 2017)

Room 111, Level 1, CCIB

11:10 - 12:00	Session 2: Drug management sessions. Part II: Biologics Lead discussant: Peter Irving, London, United Kingdom	
	11:10 - 11:30	10: Anti-TNF agents Filip Baert, Roeselare, Belgium
	11:30 - 11:45	11: Vedolizumab James Lindsay, London, United Kingdom
	11:45 - 12:00	12: Ustekinumab Marc Ferrante, Leuven, Belgium
12:00 - 12:30	Lunch break	
12:30 - 14:00	Session 3: Seminars: Part I: Special clinical situations	
	12:30 - 13:15	EITHER: 13a: Managing IBD and pregnancy Janneke van der Woude, Rotterdam, The Netherlands Iris Dotan, Tel Aviv, Israel Room 111, Level 1, CCIB OR 13b: Managing extraintestinal manifestations of IBD Stephan Vavricka, Zurich, Switzerland Peter Lakatos, Budapest, Hungary; Montreal, Canada Room 118, Level 1, CCIB
	13:15 - 14:00	EITHER: 14a: Managing IBD and pregnancy Janneke van der Woude, Rotterdam, The Netherlands Iris Dotan, Tel Aviv, Israel Room 111, Level 1, CCIB OR 14b: Managing extraintestinal manifestations of IBD Stephan Vavricka, Zurich, Switzerland Peter Lakatos, Budapest, Hungary; Montreal, Canada Room 118, Level 1, CCIB
14:00 - 14:15	Coffee break	
14:15 - 15:45	Session 3: Seminars: Part II: Long term management	
	14:15 - 15:00	EITHER: 15a: Managing complications associated with anti-TNF therapy Shomron Ben-Horin, Ramat Gan, Israel Room 111, Level 1, CCIB OR 15b: Perform endoscopy and IBD incl. chromo-endoscopy, balloon dilatation Pierre Michetti, Lausanne, Switzerland Marc Ferrante, Leuven, Belgium Room 118, Level 1, CCIB
	15:00 - 15:45	EITHER: 16a: Managing complications associated with anti-TNF therapy Shomron Ben-Horin, Ramat Gan, Israel Room 111, Level 1, CCIB OR 16b: Perform endoscopy and IBD incl. chromo-endoscopy, balloon dilatation Pierre Michetti, Lausanne, Switzerland Marc Ferrante, Leuven, Belgium Room 118, Level 1, CCIB
16:00-17:00	Industry Sponsored IBD Intensive Advance Course satellite symposium Please refer to pages page 194	

Thursday, February 16, 2017

Programme overview (as of January 16, 2017)

Room 111, Level 1, CCIB

08:00 - 10:00		Session 4: Interactive case discussions Lead discussant: Peter Irving, London, United Kingdom
	08:00 - 08:50	17: Case-based discussion: Fistulising Crohn's Disease: Medical and surgical approaches Case presentation: Antonio López-Sanromán, Madrid, Spain Discussion: Paulo Kotze, Curitiba, Brasil
	08:50 - 09:00	Discussion
	09:00 - 09:50	18: Case-based discussion: The patient with severe inflammatory Crohn's Disease Case presentation: Pieter Hindryckx, Ghent, Belgium Discussion: Laurence Egan, Galway, Ireland
	09:50 - 10:00	Discussion
10:00 - 10:20		Coffee break
10:20 - 12:15		Session 5: Special cases scenarios Lead discussant: Pascal Juillerat, Bern, Switzerland
	10:20 - 10:40	19: Pre- and postoperative management of Crohn's Disease Glen Doherty, Dublin, Ireland
	10:40 - 11:25	20: Case based discussion: Investigation and management of mild/moderate Crohn's Disease Case presentation: Tim Raine, Cambridge, United Kingdom Discussion: Jane Andrews, Adelaide, Australia
	11:25 - 11:45	21: Management of refractory pouchitis Iris Dotan, Tel Aviv, Israel
	11:45 - 12:15	22: Medical management of acute severe Ulcerative Colitis Charlie Lees, Edinburgh, United Kingdom
12:15 - 12:30		Feedback and closing remarks Peter Irving, London, United Kingdom Pascal Juillerat, Bern, Switzerland

14th IBD Intensive Advanced Course

Date:	March 16-17, 2016
Time:	March 16, 2016: 08:00-15:30 March 17, 2016: 08:00-12:30
Organisation:	EduCom
Target audience:	Junior gastroenterologists
Registration:	Upon invitation
CME accreditation:	8 CME credits, upon return of an evaluation form distributed during the course.

Wednesday, March 16, 2016

Programme overview (as of February 15, 2016)

Room E104-105, Level 1, RAI Amsterdam

07:30 - 08:00	Arrival & distribution of voting pads
08:00 - 08:15	1: Welcome Séverine Vermeire, Leuven, Belgium Gerassimos Mantzaris, Athens, Greece
08:15 - 08:45	2: Pre-course test Peter Irving, London, United Kingdom
08:45 - 09:45	Session 1: Pathogenesis Lead discussant: James Lindsay, London, United Kingdom
08:45 - 09:00	3: IBD: The role of the exposome Jonas Halfvarsson, Örebro, Sweden
09:00 - 09:15	4: The genetics of IBD Miles Parkes, Cambridge, United Kingdom
09:15 - 09:30	5: The microbiome and IBD Philippe Seksik, Paris, France
09:30 - 09:45	Discussion
09:45 - 10:15	Coffee break
10:15 - 11:00	Session 2: Interactive case discussion Lead discussant: James Lindsay, London, United Kingdom
10:15 - 11:00	6: Case based discussion: Investigation and management of mild/moderate Crohn's Disease Case presentation: Timothy Raine, Cambridge, United Kingdom Discussion: Jane Andrews, Adelaide, Australia

Wednesday, March 16, 2016, cont.

Programme overview (as of February 15, 2016)

Room E104-105, Level 1, RAI Amsterdam

11:00 - 12:00		Session 3: Seminar session - Part I: Specialist topic in IBD
11:00 - 12:00		EITHER: 7a: Managing IBD and pregnancy Janneke van der Woude, Rotterdam, The Netherlands Zuzana Zelinkova, Bratislava, Slovakia Room E104-105, Level 1, RAI Amsterdam OR 7b: Managing complications associated with anti-TNF therapy Shomron Ben-Horin, Ramat Gan, Israel Room E103, Level 1, RAI Amsterdam OR 7c: Managing extraintestinal manifestations of IBD Stephan Vavricka, Zürich, Switzerland Peter Lakatos, Budapest, Hungary Room E106, Level 1, RAI Amsterdam
12:00 - 12:30		Lunch break
12:30 - 14:30		Session 3: Seminar session - Part II: Practical skills
12:30 - 13:30		EITHER: 8a: Role of bowel ultrasonography in intestinal diseases Stephan Vavricka, Zürich, Switzerland Torsten Kucharzik, Lüneburg, Germany Room E104-105, Level 1, RAI Amsterdam OR 8b: Practical guide to interpreting MRI Gionata Fiorino, Milan, Italy Cristiana Bonifacio, Milan, Italy Room E103, Level 1, RAI Amsterdam OR 8c: Practical guide to endoscopy and IBD incl. chromo-endoscopy, balloon dilatation and reporting Matt Rutter, Stockton-on-Tees, United Kingdom Pierre Michetti, Lausanne, Switzerland Room E106, Level 1, RAI Amsterdam
13:30 - 14:30		EITHER: 9a: Role of bowel ultrasonography in intestinal diseases Stephan Vavricka, Zürich, Switzerland Torsten Kucharzik, Lüneburg, Germany Room E104-105, Level 1, RAI Amsterdam OR 9b: Practical guide to interpreting MRI Gionata Fiorino, Milan, Italy Cristiana Bonifacio, Milan, Italy Room E103, Level 1, RAI Amsterdam OR 9c: Practical guide to endoscopy and IBD incl. chromo-endoscopy, balloon dilatation and reporting Matt Rutter, Stockton-on-Tees, United Kingdom Pierre Michetti, Lausanne, Switzerland Room E106, Level 1, RAI Amsterdam
14:30 - 15:30		Session 4: Interactive case discussion
		Lead discussant: Peter Irving, London, United Kingdom
14:30 - 15:30		10: Tandem talk: IBD therapeutics targets and drugs: New and old Yehuda Chowers, Haifa, Israel James Lindsay, London, United Kingdom

Thursday, March 17, 2016

Programme overview (as of February 15, 2016)

Room E104-105, Level 1, RAI Amsterdam

08:00 - 10:20		Session 5: Interactive case discussion and lecture session Lead discussant: Peter Irving, London, United Kingdom
	08:00 - 09:00	11: Case based discussion: Fistulising Crohn's Disease: Medical and surgical approaches Antonio López-Sanromán, Madrid, Spain André D'Hoore, Leuven, Belgium
	09:00 - 10:00	12: Case based discussion: The patient with severe inflammatory Crohn's Disease Case presentation: Pieter Hindryckx, Ghent, Belgium Discussion: Laurence Egan, Galway, Ireland
	10:00 - 10:20	Discussion
10:20 - 10:45		Coffee break
10:45 - 12:15		Session 6: Special scenarios Lead discussant: James Lindsay, London, United Kingdom
	10:45 - 11:15	13: Peri-operative management of Crohn's Disease Michael Kamm, Melbourne, Australia
	11:15 - 11:45	14: Monitoring therapy with drug levels and antibody testing Peter Irving, London, United Kingdom
	11:45 - 12:15	15: The medical management of Acute Severe Ulcerative Colitis: Case based discussion Charlie Lees, Edinburgh, United Kingdom
12:15 - 12:30		16: Feedback & closing remarks Peter Irving, London, United Kingdom James Lindsay, London, United Kingdom